Latest News and Press Releases

60 Degrees and Tulane to study tafenoquine against Lyme and Bartonella bacteria, part of the “3Bs” common in tick-borne illness co-infections.

The new research, published in Frontiers in Medicine, points to the need for greater follow-up from medical professionals to address potential treatment failures. PORTOLA VALLEY, Calif., July 10,...

PORTOLA VALLEY, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, has hired Josh Wein to serve as its new executive director,...

PORTOLA VALLEY, Calif., June 12, 2025 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, has given its 2025 Emerging Leader Award (ELA) to Chao Wang,...

Clinical & Laboratory Standards Institute is partnering with LymeX Diagnostics Prize to accelerate the development of Lyme disease detection and treatment.

PORTOLA VALLEY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, announces two pre-clinical studies published in the...

60 Degrees Pharma CEO Geoff Dow, PhD, will discuss babesiosis threats and therapies at the virtual Healing Lyme Summit, April 15–21

60 Degrees Pharma partners with Yale to develop tafenoquine for treating and preventing babesiosis, a severe tick-borne disease with limited treatments.

PORTOLA VALLEY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, announces the recipient of the 2024 Emerging Leader Award...

60 Degrees Pharma wins IRB approval for tafenoquine study for treating persistent babesiosis in immunocompromised patients despite prior treatment.